CA-NETAPP
5.3.2024 14:02:00 CET | Business Wire | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced new capabilities that maximize the potential of generative artificial intelligence (Gen AI) projects and build competitive advantage for users. Customers can now take their AI projects to the next level by combining NetApp’s intelligent data infrastructure with high-performance compute, networking and software from NVIDIA.
Gen AI has captured global attention for its potential to automate tedious tasks, uncover new insights, and drive product innovation. Nearly three out of four companies are already using Gen AI, according to the NetApp 2023 Data Complexity report. To unlock the potential of Gen AI, organizations need secure, high-performance access to data spread across complex hybrid and multicloud environments. NetApp has a long and successful history of expertise in supporting AI with solutions that deliver management simplicity anywhere data lives, provide high performance without requiring new infrastructure silos, and supply trusted, secure data to drive responsible AI.
“NetApp is the intelligent data infrastructure company, with solutions optimized to maximize the potential of our customers’ AI investments,” said Arunkumar Gururajan, Vice President of Data Science & Research at NetApp. “Our unique approach to AI gives customers complete access and control over their data throughout the data pipeline, moving seamlessly between their public cloud and on-premises environments. By tiering object storage for each phase of the AI process, our customers can optimize both performance and costs exactly where they need them. Our unified approach delivers the performance, productivity, and protection customers need to quickly innovate with AI.”
To support companies leveraging Gen AI to improve their operations and strategic decision-making, NetApp released updates to its intelligent data infrastructure capabilities including:
- NetApp AIPod™ is NetApp's AI-optimized converged infrastructure for organizations’ highest priority AI projects, including training and inferencing. NetApp AIPod powered by NVIDIA DGX is now a certified NVIDIA DGX BasePOD solution using NVIDIA DGX H100 systems integrated with NetApp AFF C-Series affordable capacity flash systems to drive a new level of cost/performance while optimizing rack space and sustainability. NetApp AIPod powered by NVIDIA DGX also continues to support NVIDIA DGX A100 systems.
- New FlexPod for AI reference architectures extend the leading converged infrastructure solution from NetApp and Cisco. FlexPod for AI now supports the NVIDIA AI Enterprise software platform. FlexPod for AI can now be extended to leverage RedHat OpenShift and SuSE Rancher. New scaling and benchmarking have been added to support increasingly GPU-intensive applications. Customers can use these new FlexPod solutions as an end-to-end blueprint to efficiently design, deploy, and operate the FlexPod platform for AI use cases.
- NetApp is now validated for NVIDIA OVX systems. NetApp storage combined with NVIDIA OVX computing systems can help streamline enterprise AI deployments, including model fine-tuning and inference workloads. Powered by NVIDIA L40S GPUs, validated NVIDIA OVX solutions are available from leading server vendors and include NVIDIA AI Enterprise software along with NVIDIA Quantum-2 InfiniBand or NVIDIA Spectrum-X Ethernet, and NVIDIA BlueField-3 DPUs. NetApp is one of the first partners to complete this new storage validation for NVIDIA OVX.
To further enhance its AI leadership, NetApp also is announcing revolutionary new cyber-resilience capabilities including one of the first uses of AI/ML embedded in storage to fight ransomware. The new Autonomous Ransomware Protection with AI (ARP/AI) will provide the next generation of machine learning in ONTAP, giving the increased accuracy and performance required to detect and mitigate new, more sophisticated cyber threats.
“AI powers mission-critical use cases in every industry, from healthcare to manufacturing to financial services,” said Tony Paikeday, Senior Director of AI Systems at NVIDIA. “NetApp AIPod certified for NVIDIA DGX BasePOD provides a powerful reference architecture that helps enterprises eliminate design complexity, reduce deployment time frames, and simplify ongoing operations.”
“GenAI has massive potential to help organizations harness their data to uncover business insights and improve operational efficiency,” said Archana Venkatraman, Research Director, Cloud Data Management, IDC. “NetApp has continuously adapted to deliver the services and solutions customers need to effectively manage their data pipelines. These updates further illustrate NetApp’s willingness to evolve and bring innovations to customers that unlock the full potential of AI.”
NetApp delivers a unified approach to infrastructure and data management that eliminates data silos, brings enhanced performance and trusted data protection to customers’ AI turnkey solutions, and helps customers accelerate the time to results for their AI projects.
To learn more about the NetApp offerings to support Gen AI, visit: https://www.netapp.com/artificial-intelligence/
Additional Resources
- Your Data, Your AI, Anywhere: Introducing the NetApp AIPod Now Certified on NVIDIA's DGX H100
- FlexPod: Where Converged Meets Cloud
About NetApp
NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305729049/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom